JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Order Through VWR & Receive a FREE Sample

Support: [email protected]

Track Your Order

Home
Bioactive Compounds

Bioactive Compounds

B4825 IKKε-IN-1

Summary: potent IKKε inhibitor

Soluble in DMSO
B4918 OXF BD 02

Summary: Selective inhibitor of the first bromodomain of BRD4

<29.53 mg/mL
B4937 SB 706504

Summary: p38 MAPK inhibitor

<49.25 mg/mL
A8715 SBI-0206965

8 Citation

Target: ULK1

Summary: ULK1 inhibitor

≥24.47 mg/mL
B5904 Regadenoson

1 Citation

Target: Adenosine A2A Receptors

Summary: Highly selective and low affinity A2A adenosine agonist

insoluble in H2O; insoluble in EtOH; ≥18.05 mg/mL
B5960 PF-03394197(Oclacitinib)

Summary: Novel Janus kinase inhibitor

≥33.7 mg/mL
B5970 Sanguinarine chloride

Summary: Inhibitor of PP2C and MKP-1

insoluble in H2O; insoluble in EtOH; ≥3.68 mg/mL
A1045 Gap 27

9 Citation

Target: Gap Junctions

Summary: Selective gap junction blocker

insoluble in EtOH; ≥5 mg/mL
B2117 Pioglitazone

1 Citation

Summary: PPAR agonist

insoluble in H2O; insoluble in EtOH; ≥14.3 mg/mL
B1407 Dabrafenib (GSK2118436)

3 Citation

Target: Raf

Summary: Inhibitor of BRAF(V600) mutants

≥26 mg/mL